Aniracetam is a nootropic supplement or smart drug which was developed in the 1970’s by the Hoffman-La Roche (Belgium) company.
This compound is part of a class of nootropics known as Racetams, which are noted for their ability to promote cognitive function and increase cholinergic neurotransmission.
Aniracetam also exhibits an anxiolytic effect (meaning that it reduces feelings of anxiety) and is purported to enhance mood alongside memory and focus.
This nootropic drug has been well-studied for a number of years and is regarded as well-tolerated with minor side effects and a low level of toxicity.
However, before using Aniracetam it is important to understand what the benefits are, how this supplement works, dosages and stacks, as well as the risk of side effects.
While research shows that it can improve cognitive function in cases where there is some form of deficit or impairment, there is insufficient evidence to determine whether it works to improve cognition in healthy adults. Buy Aniracetam online at this link.



- Heightens focus & motivation
- Supports memory formation & recall
- Shown to enhance mood & reduce anxiety
Aniracetam Overview | |
---|---|
Also Known As | N-anisoyl-2-pyrrolidinone, 1-(4-methoxybenzoyl)pyrrolidin-2-one, Aniracetamum, Aniracétam, Ro 135057 |
Trade Names | Ampamet, Aniracetam-Sanhome, Memodrin, Draganon, Sarpul, Referan, Pergamid, Bi Si Ling, Bo Bang Lin, San Le Xi, Shuntan, Yi Ling Shu |
Category | Nootropic, Racetam, Ampakine |
Type | Nootropic Agent, Central Stimulant, Anxiolytic Agent, Antidepressive Agents |
Legal Status | |
Medical Uses |
|
Non-Medical Uses |
|
Mechanism of Action |
|
Dosage | 750 mg or 1500 mg per day, split into 1 – 2 administrations |
Stacked With | Piracetam, Pramiracetam, Oxiracetam, Phenylpiracetam, Noopept, Choline, Alpha GPC, Citicoline, Centrophenoxine, DMAE, Phosphatidylcholine, Adderall, Modafinil (Provigil), Phenibut |
ATC Code | N06BX11 (WHO): N06 Psychoanaleptics > NO6B Psychostimulants, agents used for adhd and nootropics > NO6BX Other psychostimulants and nootropics |
CAS Registry Number | 0072432-10-1 |
Chemical Formula | C12-H13-N-O3 |
Molecular Weight | 219.24 g/mol |
Administration | Oral, Intravenous |
Absoprtion | Rapidly and completely absorbed from the gastrointestinal tract |
Absolute bioavailability | 0.02% due to extensive biodegradation |
Metabolites |
|
Excretion |
|
Biological Half-life | 1 – 2.5 hours |
What is Aniracetam?
Related Topics
- What is Aniracetam?
- User Reviews
- Effects and Benefits
- Aniracetam for Anxiety
- Dosage Suggestions
- Using Aniracetam Powder
- Best Way to Take
- Side Effects
- Aniracetam for Sale
- Buyer's Guide
- Is Aniracetam Legal?
- Stacking with Piracetam
- Stacking with Choline
- Comparison to Piracetam
- Comparison to Oxiracetam
- Comparison to Pramiracetam
- Comparison to Noopept
Aniracetam is also known as N-anisoyl-2-pyrrolidinone, Referan, Draganon, Pergamid, Sarpul, Ampamet, and Memodrin.
It was developed as a more powerful analog of the nootropic drug Piracetam (Nootropil). The name “Aniracetam” comes from the Japanese prefix “Ani” which translates to “big brother.”
It is said to be 3-6 times more potent than Piracetam and has greater oral bio-availability, in part due to the fact that it is fat soluble (lipophilic).
This nootropic has been sold in Europe as a prescription drug for the treatment of several cognitive disorders, but it has not been approved for use in the United States.
It is the archetype of the ampakine class of nootropics and has the chemical structure of a racetam because it shares a pyrrolidone nucleus.
All racetam nootropics are synthetic (man-made) chemicals that work by influencing receptors for the neurotransmitter acetylcholine. Aniracetam also works by affecting AMPA receptor sites for the neurotransmitter glutamate.
Together, these two excitatory neurotransmitters are believed to be responsible for memory formation, recall, focus, thinking and related cognitive processes.

- Improves memory and learning
- Heightens focus and motivation
- Enhances mood and reduces anxiety & stress
Benefits of Aniracetam
The purported benefits of Aniracetam are primarily related to improved mental performance and mood.
It has been studied for its nootropic effects on memory, cognition, attention and learning capacity.
Research suggests that it may support processes related to both long-term memory formation and short-term memory processing (working memory).
This supplement is anecdotally said to improve mental focus and reduce distractibility. Many users note that their attention span is increased as well as being able to focus and concentrate much more easily.
It serves to improve mental fluidity for some users, making even simple, routine tasks such as reading and writing (and holding conversations) seem to flow much more easily, without expending as much effort as before using Aniracetam supplements.
According to user testimonials, some individuals experience a stimulating effect when taking this nootropic agent while others experience a sensation of relaxation and calm as well as attenuation of depressive feelings.
Aniracetam is often used by individuals with social anxiety to produce a calming anxiolytic effect before engaging in social activities. However, it has not been approved by the FDA as a drug for the treatment of anxiety or related mood disorders.
Many of the benefits reported above are based on user experiences and testimonials. Not everyone will respond to this nootropic in the same way. Some individuals do not experience benefits when taking Aniracetam and may see an exacerbation of brain fog or reduced mental clarity.
Aniracetam vs. Piracetam
Aniracetam is purported to be more powerful than Piracetam, requiring a dosage between 3 – 5 times lower than this original nootropic.
Aniracetam was first developed by modifying the Piracetam molecule. This change resulted in significant faster action (as well as breakdown) in the body and a slightly different profile of effects.
It is theorized that Aniracetam is more potent because it has greater oral bioavailability. This nootropic is fat-soluble and is better absorbed from the gut.
The effects of Aniracetam are described as kicking in much faster than Piracetam. It is also considered to have more of a stimulating effect and a discernable mood-enhancement effect.
Aniracetam users report that this nootropic boosts focus, motivation, attention and confidence to a greater degree than Piracetam.
Conversely, Piracetam has less of an effect on depression, anxiety or sociability and tends to produce a more relaxed feeling of mental clarity. The effects of Piracetam also tend to last for a longer period of time.
In one comparative research study, dosages of 1500 mg oral Aniracetam were compared to 2400 mg of oral Piracetam. Note that this is significantly lower than the typical therapeutic dosage of Piracetam used today, which is between 4800 mg to 9600 mg per day.
In this study, healthy volunteers between the ages of 19 to 34 years old were given scopolamine, which is a drug used to induce cognitive impairment. Participants given the aniracetam performed superior to those given a placebo, while those taking Piracetam did no better than those on the placebo.
In another 6-month, double-blind study participants were given 750 mg of Aniracetam twice a day or 800 mg of Piracetam three times daily.
Participants were 115 patients diagnosed with mild to moderate SDAT based on the criteria established by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA).
Participants were tested for 18 different variables at baseline and after 6 months of treatment. Those given Aniracetam showed significant improvement on 17 of the 18 scores measured, compared to only 9 out of 18 for those given placebo.
Furthermore, Aniracetam was found to be more effective than Piracetam on 8 of the tested variables. Because this study did not include a control group given a placebo, the results cannot clearly be interpreted.
However, the findings suggest that a 1500 mg per day dosage of Aniracetam is more effective for the treatment of cognitive deficits than a 2400 mg per day dosage of Piracetam.
How Aniracetam Works:
While the exact method of action for Aniracetam is still not completely understood, there are several theories about how this nootropic works.
It is known to cross the blood-brain barrier and affects several key brain chemicals called neurotransmitters.
Aniracetam binds to acetylcholine receptors, causing this neurotransmitter to remain active in the brain for an extended period of time.
This action is thought to be primarily responsible for the majority of its cognitive benefits since this neurotransmitter is a vital player in many cognitive processes (especially memory, learning and focus).
There is also thought to be some modulation of additional chemicals within the brain. These are Dopamine, Gamma-Aminobutyric Acid (GABA) and Serotonin.
Dopamine is thought to be primarily responsible for functions like mood and movement. Serotonin is an inhibitory neurotransmitter chemical that helps to regulate sleep and wake cycles, among other things.
By promoting activity in these chemical receptor sites, the supplement is possibly able to help in the areas of improving anxiety and other mood issues.
Multiple animal studies demonstrate that this nootropic has a neuroprotective effect by improving glucose metabolism and preventing the generation of free radical molecules. It is believed to have anti-oxidant benefits for brain cells.
Aniracetam has also been shown to protect against excitotoxicity caused by overactivation of glutamate receptors. When the receptors for the neurotransmitter glutamate are over-stimulated, it can result in damage to neurons and cause premature neuronal death.

- Focus longer, clear brain fog & feel more motivated
- Boost energy, alertnes & memory
- Contains 12 safe and natural nootropic ingredients
Mechanism of Action
Below are some of the mechanisms of action for this smart drug observed in research trials.
Cholinergic Receptors: Aniracetam is a positive modulator of the nicotinic class of acetylcholine receptors. This means it increases activity at nicotinic receptors in the brain, which are linked to focus, memory and cognition.
In animal studies, rodents that are given cholinergic antagonists (drugs that block activity at acetylcholine receptors) are known to experience dysfunction in memory and learning.
When giving those rodents Aniracetam, this nootropic is able to reduce the deficits caused by cholinergic antagonists.
Aniracetam has also been shown to increase the release of acetylcholine from the hippocampus in the brain. The hippocampus is the part of the brain responsible for the consolidation of short-term memory to long-term memory.
AMPA Receptors: Aniracetam positively modulates the AMPA class of glutamate receptors in the brain. Glutamate is the most common excitatory neurotransmitter in the brain.
AMPA stands for Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid. This class of receptors is involved in memory, synaptic plasticity and fast synaptic transmission.
Research shows that aniracetam binds to non-active sites of this receptor and modulates these receptors to reduce the rate at which they become desensitized. The result is that when an AMPA receptor agonist like glutamate binds to the receptor, its activation is enhanced.
It is unclear what specific effect this has on memory and learning in humans. It has been theorized that increasing the activation of AMPA receptors may increase Long-Term Potentiation, which is how memories get stored in the brain.
The theory is that use of Aniracetam can make it easier for new memories to form and to be retained. However, this has not yet been demonstrated in human research trials on healthy adults.
Adrenergic Receptors: One of the secondary effects of increased AMPA receptor activation is greater release of noradrenaline from neurons. Noradrenaline is a stimulatory brain chemical that increases alertness, focus and energy.
It is part of the body’s fight-or-flight stress response. When noradrenaline levels are higher, the result is greater arousal, vigilance, attention, cognitive function, anxiety and restlessness.
Due to the mild stimulant-like properties of Aniracetam, it may disrupt sleep patterns if taken late in the day.
GABAergic Receptors: Aniracetam is reported to enhance the inhibitory effect of the GABA neurotransmitter (Gamma-Aminobutyric acid). GABA has a calming effect on the brain and may be responsible for mediating the purported anxiolytic effect of this nootropic.
Serotonergic Receptors: Aniracetam is thought to prevent the breakdown of serotonin at its receptor sites. This is a neurotransmitter involved in mood regulation, sleep, anxiety and feelings of contentment.
Serotonin is sometimes referred to as the “Happy Hormone”. By inhibiting its breakdown after it has been released from a neuronal vesicle, Aniracetam may cause greater activation of serotonin receptors in the brain.
Dopaminergic Receptors: This nootropic is observed to increase the release of the neurotransmitter dopamine, which can cause greater activation of the dopaminergic receptor system.
Dopamine is involved in mood, attentional control, motivation, desire and the reward system feedback loop. Some sources attribute the benefits of Aniracetam for focus and motivation to increased dopamine activity.
While all of these mechanisms of action have been observed in animal research studies, more research is needed to pinpoint how Aniracetam works in humans. People respond differently to the effects of this smart drug and more needs to be understood about its neurological effects.
Treatment of Cognitive Impairment
In one 1994 meta-review of the therapeutic effects of Aniracetam, positive results were described for the treatment of senile cognitive disorders.
In the study described, elderly patients diagnosed with mild to moderate cases of cognitive impairment were given 1,500 mg per day for four to six months.
Patients all exhibit signs of senile dementia associated with Alzheimer’s disease. They were given 18 different tests to measure their cognitive function.
After the trial, the Alzheimer patients given 1,500 mg of Aniracetam performed better than the control group given a placebo across 18 of the 18 different tests performed.
Another treatment group in the trial was given 2,400 mg of Piracetam per day. Compared to the patients given Piracetam, those given Aniracetam performed better on 8 of the 18 tests after the 6 month trial period.
Aniracetam ADHD Treatment
Aniracetam is sometimes used as an off-label remedy for ADHD (Attention Deficit Hyperactive Disorder and ADD (Attention Deficit Disorder).
There have not been any research studies conducted into the use of this nootropic for this purpose and it has not been approved by the FDA in the United States as a treatment for this medical condition.
Research studies suggest that there may be benefits for cognitive function and behaviors related to attentional control and impulsivity, but it has yet to be studied in a population of individuals diagnosed with this condition.
The related nootropic Piracetam was studied for its therapeutic effects on ADHD in children at dosages of either 70 mg/kg of bodyweight daily or 40 mg/kg.
Both groups saw improvements in behavioral characteristics, motor coordination and assessments of attention. The treatment group given the higher dosage experienced a 60% response rate, while those given the lower dosage saw a 43% response rate.
Mood, Anxiety and Depression
User reviews of Aniracetam capsules suggest a mood enhancement effect that is described as increasing positive emotions, boosting confidence, promoting relaxation and inhibiting negative thoughts.
Aniracetam demonstrates several mechanisms of action that can promote benefits for mood, depression and anxiety. It has a strong anxiolytic effect, attributed to its ability to stimulate GABA receptors in the brain.
One of the metabolites of this nootropic agent is N-anisoyl-GABA (4-p-anisaminobutyric acid), which is an analogue for the neurotransmitter gamma-amino-butyric acid.
Following oral ingestion in humans, 70% of Aniracetam is quickly broken down or converted into n-anisoyl-GABA. It appears that this metabolite is responsible for many of the effects of Aniracetam on mood and cognition.
It is unclear how specifically Aniracetam stimulates GABA receptors. Aniracetam decreases kainate receptor sensitivity, which may help to prevent excessive excitatory signalling. Aniracetam may also have a direct effect on these receptors.
One theory is that N-anisoyl-GABA can bind to and activate GABA receptors, resulting in an anxiolytic response. GABA is the chief inhibitory neurotransmitter in the brain, working to prevent over-stimulation of neurons that can lead to feelings of anxiety.
In people who have social anxiety, general anxiety disorder, paranoia or who commonly experience stress and anxious thoughts, taking a GABAergic drug may help to calm those overactive thoughts. Benzodiazepines and phenibut both work by stimulating GABA receptors in the brain.
N-anisoyl-GABA can also stimulate Group II metabotropic glutamate receptors, which play a role in enhancing the release of acetylcholine (ACh) in the prefrontal cortex.
N-anisoyl-GABA has also been shown to stimulate the release of Dopamine (DA) and Serotonin (5-HT) in the pre-frontal cortex (PFC), Ventral tegmental area (VTA) and dorsal raphe nucleus (DRN).
In a research study, N-anisoyl-GABA was directly perfused into the relevant regions in the rat brain. Results showed that this Aniracetam metabolite (along with the metabolite p-anisic acid) resulted in enhanced release of dopamine and serotonin.
These are two of the neurochemicals closely connected to mood regulation, feelings of pleasure and relaxation.
Dopamine is involved in the reward feedback loop and is responsible for our ability to direct our efforts towards a goal. It is an excitatory neurotransmitter that plays a role in focus, pleasure, motivation and executive function.
Serotonin is an inhibitory neurotransmitter that is linked to feelings of satisfaction, comfort, relaxation, calm as well as being involved in sleep regulation. Increasing serotonin activity is purported to alleviate anxiety and feelings of nervousness.
By influencing the release of these two mood-regulating brain chemicals, Aniracetam may be able to promote a mood-lifting effect and increase social behaviour.
Aniracetam Dosage:
The prescribing information for this medication generally recommends a dosage of 600mg, 750mg, 1000mg or 1500mg per day.
It is recommended to start with a low dose of Aniracetam to gauge individual tolerance and to titrate based on effects observed. Dosages may be gradually increased until the lowest effective dosage is achieved.
In research studies on Aniracetam’s clinical use, dosages of 600mg to 2000mg per day have been administered for the treatment of memory disorders and cerebrovascular disease.
In Japan, patients with anxiety or depression linked to a cerebral infarction are recommended to take dosages of 200 mg, three times per day.
Patients diagnosed with Senile Dementia of the Alzheimer’s Type (SDAT) have been given dosages of 1000mg – 1500mg daily, administered in one dosing or as two 750mg oral tablets taken twice a day.
Elderly individuals experiencing memory deficits or attention disorders with vascular origin have also been given 1500mg in a single dose or split into two dosages per day.
A typical dosage for nootropic benefits is 1.5 grams split between three times per day.
It should be taken early in the day to avoid disruptions to your sleep cycle. Due to its stimulant-like effects, use of this nootropic late in the day could cause or worsen insomnia symptoms.
Aniracetam is usually stacked with a choline supplement to increase efficacy and prevent some side effects. A dosage ratio of 4:1 or 5:1 is often recommended.
This means that for every 1 gram of Aniracetam you should consume 200 – 250mg of choline. Some examples of supplements that contain choline include CDP Choline, Alpha GPC, Lecithin and Choline Bitartrate.
This nootropic usually comes in the form of a film-coated tablet or oral capsule. It is also sold in granule or bulk powder form. The most common dosages are 750mg and 1500mg per serving.
The granules or powder are usually mixed into water or milk to be swallowed. Due to the unpleasant taste perceived by some people, the oral pills are generally the preferred method for taking Aniracetam.
Pills or granular mixtures may contain additives and non-medicinal ingredients such as sodium amide glycolate, sorbitol, dioctyl sodium sulfosuccinate, balsamic aroma, sodium cyclamate, methyldroxy propyl cellulose, sodic saccharine, saccharose, grapefruit aroma, fructose, mint aroma, banana aroma, aspartame, xylitol, magnesium stearate, titanium dioxide, methyldroxy propyl cellulose or E 172.
Determine whether you have an allergy to any of these additives or artificial sweeteners before deciding which form of Aniracetam to buy. There are a number of different formulations available on the marketplace.
Intravenous aniracetam has also been used in some research studies and as a clinical therapy for certain medical conditions. As an IV treatment, it is typically administered at a dosage of 10 or 100 mg.
How to Take Aniracetam
Research studies show that it is well-absorbed from the gut even on an empty stomach. However, consuming it with a fat source is presumed to increase absorption and to minimize negative effects on the gastrointestinal tract.
It is advised to take this nootropic 15 minutes after consuming a meal rich in good fats. Some examples of brain-healthy fats include fish oil, egg yolks, whole milk, high-fat yogurt, almonds, salmon and other fatty fish.
Aniracetam has low bioavailability, which means that only a small amount of the dosage consume will be active and pass through the blood-brain barrier.
You should take the medicine at the same time every day. In case you miss a dose of Aniracetam, it is recommended to take this skipped dosage as soon as you remember and to adhere to a regular schedule of administration.
If it is almost time to take your next regular dose, skin the missed dose. Do not take a double dose to compensate for a forgotten dose.
Consult with a licensed doctor and pharmacist to determine the right dosage of this nootropic for you. Check with them about adjusting the dosage if you are using any prescription or over-the-counter medications, dietary supplements, herbal products or nutritional vitamins.
How Long Does It Take to See Aniracetam Effects? Aniracetam is considered to be a fast-acting nootropic agent and some users report experiencing improvements immediately upon use.
The first signs that Aniracetam is working can include increased mental attention, sharper visual perceptions with brighter colors, greater arousal or a subtle improvement in memory.
It is believed to be rapidly absorbed from the gut and circulated through the body. Pharmacokinetic research suggests that it takes approximately 2 hours for peak plasma concentrations to be achieved.
While some effects may be noticeable in the short-term, prescribing information for this nootropic suggests that many of the benefits can take longer to develop. According to one source, “The therapeutic effect of Aniracetam is seen after about 60 days and may be more pronounced after 4 months of treatment.”
What is the half-life of Aniracetam? This nootropic has a half-life of 1 – 2.5 hours, which is one of the shortest among racetam drugs. Upon oral ingestion, it is rapidly degraded by first pass hepatic metabolism.
When you consume this supplement orally, it is quickly broken down in the body by the liver and eliminated as the metabolites N-anisoyl-GABA, 2-Pyrrolidinone and p-anisic acid.
Dosages are taken multiple times a day to increase the duration of effects. Sources recommend that users take Aniracetam dosages two or three times during the day: morning, afternoon and early evening.
Aniracetam powder is water insoluble and fat soluble; it should be consumed with a meal to increase absorption from the gastrointestinal tract. Consuming it with milk, fish oil or other sources of healthy fats is recommended to improve oral bioavailability.
Can you Overdose on Aniracetam?
This nootropic exhibits a low degree of toxicity and there is a low risk of overdosing. In animals studies, the LD50 (lethal dose required to kill 50% of treatment subjects) for rats is observed to be 400x greater than the recommended dosage.
If you do accidentally consume an overdose and experience negative effects, seek out medical assistance immediately.
Aniracetam Stacks:
Among nootropic users, it is common to stack Aniracetam with other racetams to achieve synergistic benefits.
The general idea is that by combining several supplements together, a user may experience greater benefits than if you were to use a single nootropic in isolation.
One popular nootropic stack involves combining Aniracetam with Piracetam and Oxiracetam or cycling between these nootropics.
Another common supplement to use is Alpha GPC or another high quality Choline source. This is thought to potentiate the effects of all of Racetam nootropics which work by activating cholinergic receptors in the brain.
Below are some of the nootropic supplements commonly stacked with Aniracetam:
- Piracetam
- Oxiracetam
- Pramiracetam
- Phenylpiracetam
- Noopept
- Modafinil/Provigil
- Adrafinil
- Armodafinil/Waklert
- Choline Bitartrate
- Alpha Glycerlphosphorylcholine
- Phosphatidylcholine
- Phosphatidylserine
- CDP Choline (Citicoline)
- DMAE Bitartrate
- Phenibut
- Bacopa Monnieri
Clinical Uses:
In certain Eastern European countries, there are a number of clinical uses for Aniracetam. It was first introduced as a clinical drug in 1993.
There is ongoing research being conducted into its effects on conditions related to Alzheimer’s disease, age-related memory loss and cognitive decline or mild cognitive impairment.
While it has not been researched as a treatment for ADHD, reviews by some patients indicate it may have benefits for improving concentration and behavioral control.
Due to its effects upon the Dopamine and Serotonin receptors, there is also interest in using Aniracetam to address certain mood disorders. It is commonly taken off-label by individuals with nervousness or anxiety and mild depression.
It may also help to improve motivation and sleep disorders. There is also evidence to suggest it is helpful at treating incidents of motion sickness. Finally, Aniracetam is now being touted as an anti-aging supplement.
Experimental research studies on humans and animals suggest potential benefits of Aniracetam dosages for restoring cognitive function in various models of disease.
Studies have been conducted on the effects of Aniracetam in addressing the psychological and behavioral symptoms of elderly patients with dementia as well as patients with disorders of the Central Nervous System.
It has also been studied for its effects on cognitive function in patients following a stroke and in the treatment of slight-moderate brain decay.
It is reported to improve motor function, intellectual function and neuropsychiatric symptoms in patients diagnosed with Parkinson’s disease and progressive supranuclear palsy.
Aniracetam has also been studied in animals for its potential effects in recovering cognitive function across a number of different models of cerebral dysfunctional disorders.
It has been studied on models of depression, bladder overactivity, anxiety, fear, hyperactivity, impulsive behavior, inability to pay attention (hypoattention), and impaired REM sleep.
These studies have indirectly examined the potential role of Aniracetam for chronic fatigue syndrome, social withdrawal, schizophrenia, post-traumatic stress disorder, autism, personality disorders and sleep disorders.
It is important to note that most of this data comes from animal studies and pre-clinical trials. There is insufficient evidence to rate the effectiveness of Aniracetam for the treatment of these conditions.
Potential Side Effects:
The potential side effects when taking Aniracetam are normally quite mild, but can be more serious in some cases. For most people who experience any side effects at all (and the vast majority will not), the most common is headaches.
It is believed that racetam nootropic drugs may deplete choline stores in neurons by stimulating receptors for the neurotransmitter acetylcholine, which is synthesized from choline.
Some have hypothesized that increased acetylcholine activity could diminish choline levels in brain cells, which could result in headache symptoms developing.
While this has yet to be proven through research studies, observations of nootropic users indicate that combining Aniracetam with a choline source can eliminate the side effects.
Adding a form of Choline like the supplement Alpha GPC or Citicoline (CDP Choline) to your stack in the appropriate dosage ratio may help to alleviate the headaches and other minor side effects.
Additional Aniracetam side effects are reported to be mild. Some negative effects discussed in user reviews and research studies include:
- Restlessness
- Anxiety/Agitation
- Brain Fog
- Sleeplessness/Insomnia/Somnolence
- Vivid Dreams/Nightmares
- Vertigo
- Mild Epigastric Pain
- Diarrhea
- Skin Rash/Allergic Reaction
If these occur it is usually due to an excessive dose. Reducing the dosage is usually sufficient to experience a decline in side effects.
In one study of Alzheimer’s patients taking 1,500 mg of Aniracetam per day for 6 months, no dangerous side effects were observed. The study also found that this nootropic medication did not increase liver enzymes or demonstrate any signs of toxicity on the body.
This is in line with findings from rodent studies which show that it is non-toxic.
However, there is limited safety information available on Aniracetam from clinical trials involving human use. There is insufficient data to determine whether it is safe for long periods of time and what the risk of severe side effects is.
Certain individuals may experience a higher prevalence of negative effects. There are significant differences reported in how this nootropic affects people, according to testimonials posted online.
While many are able to use Aniracetam without experiencing negative effects, some notice side effects right away and decide to stop taking the drug.
Below is more information on the potential side effects that can occur when taking Aniracetam and other racetam nootropics.
Brain Fog
Brain fog is a subjective description for a feeling of a lack of mental clarity and focus. It is generally associated with confusion, inability to grasp facts and unclear thoughts.
Some individuals say that taking Aniracetam can cause a worsening of brain fog and impaired cognitive function, memory impairment and a general “spaced out” feeling.
It is unclear why some users can experience worse mental clarity when taking Aniracetam while others experience better clarity and focus. This is one of the least well-understood side effects of this nootropic.
To gauge your individual response to the effects of this cholinergic stimulant, it is important to start with a small dosage and only increase if you do not experience side effects.
Insomnia and Sleep Delay
Due to the mild stimulant-like effects of this nootropic, it can cause disturbances to the sleep cycle, especially if taken late in the day. It is recommended to take this nootropic in the morning or early afternoon at the latest.
Aniracetam may cause insomnia in some individuals and may worsen pre-existing sleep disorders. Use of Aniracetam with choline may further exacerbate insomnia and make it difficult to fall asleep at night.
Anxiety and Restlessness
Some aniracetam reviews cite benefits for anxiety, stress and tension. However, other users feel a worsening of anxious thoughts, irritability and restlessness.
Taking Aniracetam may trigger uncontrollable or racing thoughts, nervousness, mild paranoia, general unease and discomfort as well as social anxiety.
Some user experience logs say that this nootropics results in an increase in “mental chatter” or excessive thought loops. Several reviewers state that it is difficult to “turn their minds off” after taking this nootropic, especially late in the day.
Users have also described feelings of agitation, restlessness and over-excitation resulting in the urge to move constantly.
This may be linked to the stimulatory properties of the drug that accompany increasing cholinergic activity, glutamatergic neurotransmission and dopaminergic transmission.
Reducing the dosage or adjusting your nootropic stack can help to reduce symptoms of anxiety and over-activity.
Jaw Tension and Muscle Pain
Some users report jaw tension, pain and general muscle tension when using Aniracetam products. This has been attributed to changes in acetylcholine function, either by decreasing or increasing the availability of this neurotransmitter.
Though rare, some users also describe chest pain and muscle aches associated with use.
Nausea and Stomach Discomfort
Oral consumption of Aniracetam powder may cause nausea and stomach upset. The powder has an unpleasant taste to some. Nausea may be reduced by consuming this nootropic in pill form or taking it with food.
Due to the adrenergic effects of this nootropic, Aniracetam may also cause gastrointestinal distress and the feeling of “butterflies” in your stomach. This may be especially prevalent in individuals with a low sensitivity to stimulants.
Generally, the stomach ache and nausea subside after you have used this nootropic for several days. If it continues to bother you, consult with a doctor to determine whether there is a better alternative for you.
Some people may experience diarrhea shortly after taking their dosage of Aniracetam. This side effect is usually prevented by consuming this nootropic drug with food.
Temperature Changes
Some individuals report changes in their body temperature after taking Aniracetam tablets. It may cause you to feel abnormally hot, sweaty and flushed or it may cause you to feel cold – especially in your extremities like the hands and feet.
In some individuals, night sweats have been reported when taking racetam nootropics. If these symptoms persist and are uncomfortable, it may be necessary to use a lower dosage or to ask a doctor about alternatives.
Skin Rash and Itching
In rare cases, Aniracetam may cause skin rashes, itchiness, dry skin or hypersensitivity. This may be worse in individuals with pre-existing skin conditions or those who suffer from allergies.
It is not clear what the mechanism of action is that could lean to skin rashes, but it may be due to increased levels of histamine, which is a neurotransmitter involved in immune responses.
The risk of skin rashes may increase when combining Aniracetam with other pharmaceutical agents.
Fatigue or Apathy
While some users feel greater energy levels and motivation when taking Aniracetam, others may experience symptoms of apathy and fatigue.
According to some sources, proper timing of dosages and concomitant use of choline can help to alleviate tiredness brought on by this nootropic.
Individuals have experienced an emotional blunting or dampening effect when taking Aniracetam. This may be felt as a suppression of excitement, emotion, drive or pleasure. In most cases, this is not a severe effect.
However, individuals who have a history of mood disorders or who have used drugs to address mood problems may be more susceptible to this effect. If it becomes bothersome, consult with a doctor and it may be recommended to discontinue use.
Vertigo or Dizziness
Some individuals have described dizziness and vertigo after taking an Aniracetam dose. This may manifest as a feeling of light-headedness, spinning or instability on your feet.
In some cases, vertigo may be alleviated by lying down and closing your eyes.
This is usually associated with an excessively high dosage or with combining aniracetam with other drugs or supplements.
Tinnitus (Ringing in the Ears)
Tinnitus is reported in a small number of cases. This is described as a mild to severe sound of ringing in the ears. In severe cases, tinnitus can make it difficult to focus or fall asleep.
While some user reviews suggest that Piracetam and Aniracetam can improve tinnitus symptoms, others may feel a worsening of the effects or may develop a new case of tinnitus.
The supplements vinpocetine or ginkgo biloba may help in treating acute tinnitus.
Tolerance and Withdrawal
Some nootropic users say that they develop a tolerance to the effects of Aniracetam, resulting in the drug losing effectiveness over time.
Some of these individuals may compensate by cycling their dosages or by increase the dose to maintain the effects. Sudden withdrawal of this nootropic agent should be avoided if possible.
This could potentially lead to the development of withdrawal symptoms when you stop taking Aniracetam pills or powder. While rare, withdrawal symptoms may include brain fog, low energy, anxiety, irritability or headache.
There may be side effects in addition to those listed above. Consult with a doctor if you experience an adverse reaction and discontinue the use of this drug until you have been cleared to use it again.
Decreasing the dosage or the frequency with which you use Aniracetam may eliminate side effects. Adverse reactions may also be improved by adjusting the nootropic stack you are using.
Contraindications
The use of aniracetam may be contraindicated for people with certain medical conditions. In cases of renal (kidney) or hepatic (liver) dysfunction, a lower dosage is recommended to avoid straining kidney function.
Aniracetam may worsen the symptoms of Huntington’s chorea, which is an inherited disorder that can cause uncoordinated body movements and impaired mental abilities.
Use of this nootropic agent is also contraindicated in case of pregnancy or breastfeeding mothers due to a lack of available research. While teratogenic effects (birth-defect causing effects) have not been observed in association with this drug, it is recommended to avoid use out of an abundance of caution.
If the patient exhibits hypersensitivity to the effects of Aniracetam, use of the product should be discontinued.
Drug Interactions
Aniracetam may interact with a number of different drugs, supplements and other substances with psychoactive effects. Some of these interactions may be negative and some may be positive.
This nootropic is believed to have a low risk of interactions. According to the authors of the Hellenic AMNESIA study, “The excellent tolerability profile of aniracetam and the absence of remarkable drug interactions allow its widespread clinical use in patients with cognitive disorders, both as monotherapy and as part of combined treatment.”
Despite this, caution is still recommended before adding this smart drug to your daily routine.
Be careful when co-administering this nootropic with other compounds or medications. If you are taking pharmaceutical drugs prescribed by a doctor for the treatment of a specific medical condition, consult with your doctor or pharmacist first before using this nootropic.
Aniracetam is believed to interact with other Racetam smart drugs, such as piracetam, pramiracetam, oxiracetam, phenylpiracetam, coluracetam and nefiracetam. It may result in synergistic effects, meaning that a lower dosage is required.
This nootropic may also interact with precursors for the neurotransmitter acetylcholine, resulting in increased potency of the effects. Aniracetam has been shown to heighten the uptake and utilization of acetylcholine.
Supplements that can have a positive interaction with Aniracetam by raising acetylcholine availability include Choline Bitartrate, Choline Citrate, Choline Chloride, Acetyl-L-Carnitine (ALCAR), CDP Choline (Citicoline), Alpha GPC, DMAE, Phosphatidylserine (PS), Phosphatidylcholine, Centrophenoxine or Lecithin.
Aniracetam may interact with drugs prescribed for other medical conditions as well as recreational drug use.
Consult with your doctor before taking this nootropic if you currently are on medications that interact with the cholinergic system (such as scopolamine), anti-depressant medication or pharmaceutical agents that inhibit the absorption of lipids (fats) from the gastrointestinal tract.
Aniracetam can interact with alcohol and cause an increase in the intoxicating effects of drinking. Concomitant use is best avoided as this combination may affect you in different ways and lead to greater impairments in motor function, behavior control and decision making.
Do not drink alcohol and drive if you are using Aniracetam. You may be unaware of the increased intoxication you are experiencing due to the lower tolerance to the effects of alcohol.
Because this drug has not been approved for use by the FDA, there is not a standardized drug monograph or list of comprehensive interactions available.
It is likely that Aniracetam will interact with many of the same drugs that Piracetam and other Racetam nootropics can interact with. Below is a list of some of the medications that are known to interact with Piracetam:
- Warfarin
- Thyroid Hormones T3 + T4
- Levothyroxine
- Liothyronine
- Desiccated Thyroid Extract
- Cilostazol
- Clopidogrel
- Dipyridamole
- Eptifibatide
- Prasugrel
- Ticlopidine
- Tirofiban
Where to Buy Aniracetam
Aniracetam and related nootropics like Piracetam are not approved by the FDA (Food and Drug Administration) in the United States. They are considered investigational drugs and cannot legally be sold as medications intended for human consumption.
However, Aniracetam and other racetam nootropics are not controlled substances and are therefore legal to possess and consume if you live in the USA. This is also true for individuals who live in Canada, the United Kingdom or Australia.
As such, it is legal to purchase Aniracetam in powder form or in capsules from international vendors and to use it for personal use.
In both Italy and Switzerland, it is a licensed drug and requires a prescription to buy. In Japan, it was previously sold as a licensed drug, but was pulled from the market following a negative study result.
There are numerous online vendors who supply this product in a bulk powder. However, it is important to purchase from a provider who conducts appropriate lab testing of their product to ensure quality standards.
You are recommended to only purchase nootropic supplements from websites that provide a COA (Certificate of Authenticity) demonstrating that the Aniracetam they are selling is genuine and does not contain impurities or biological contaminants.
Some of the most popular vendors include NootropicsDepot, Peak Nootropics, Pure Nootropics and Absorb Your Health.
Aniracetam can be purchased in either powder, tablet or capsule form. Individuals who purchase the powder often purchase empty gelatin capsules to fill their own at home.
Pharmacokinetic Properties
Aniracetam has an oral bioavailability of between 8.6 – 11.4%. This makes it more bioavailable than Piracetam, but less than other nootropics like Noopept or Piracetam.
Bioavailability is a measure of how much of the drug is absorbed by the body and transported to its target action site.
After oral ingestion, this nootropic agent is rapidly absorbed from the gastrointestinal tract and circulated to the brain.
Aniracetam can be consumed with or without food; pharmacokinetic data suggests that it is rapidly absorbed from the gut even in a fasted state on an empty stomach. [99]
Because this racetam is fat-soluble, it is presumed that taking it with a fat source will increase the bioavailability. This has not been investigated in research studies, but anecdotal user reviews show that it is commonly taken with fatty acids or beverages that contain lipids.
Oral administration results in peak plasma levels within 2 hours. This means that it reaches the highest concentration in your blood within 2 hours after taking it.
After giving a 300 mg and 1200 mg oral dose of this nootropic, peak plasma concentrations were 2.3mcg/L and 14.1mcg/L respectively. After absorption, 66% of the drug exists in a state bound to plasma proteins.
In one animal study, 100 mg of Aniracetam taken intravenously resulted in an average steady state volume of distribution of 2.5 L/ kg. [99]
Aniracetam has a median active half-life of 1 to 2.5 hours and has an elimination half-life of 35 minutes after administration.
It is primarily metabolized by the liver (hepatic metabolism). In humans, 70% of Aniracetam is converted into N-Anisoyl-GABA (4,p-Anisaminobutyric acid). Other metabolites include 2-pyrrolidinone, and p-anisic acid.
These metabolites have demonstrated efficacy in animal studies for improving learning and memory. This suggests that one of the ways in which Aniracetam works is as a pro-drug for
This drug is then eliminated from the body in the form of urine (84%), carbon dioxide (11% ) and feces (0.8%) within 48 hours from oral ingestion. [99]
- Elston TW, Pandian A, Smith GD, Holley AJ, Gao N, Lugo JN. Aniracetam does not alter cognitive and affective behavior in adult C57BL/6J mice. PLoS One. 2014
- Koliaki CC, Messini C, Tsolaki M. Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study. CNS Neurosci Ther. 2012
- Papandreou G, Zorpas K, Archontaki H. Development and validation of a liquid chromatographic method for the simultaneous determination of aniracetam and its related substances in the bulk drug and a tablet formulation. J Pharm Biomed Anal. 2011
- Rial D, Takahashi RN, Morato GS. Aniracetam and DNQX affect the acquisition of rapid tolerance to ethanol in mice. Pharmacol Biochem Behav. 2009
- Dubiela FP, Queiroz CM, Moreira KD, Nobrega JN, Sita LV, Tufik S, Hipolide DC. AMPA receptors mediate passive avoidance deficits induced by sleep deprivation. Behav Brain Res. 2013
- Tian Y, Zhang JJ, Feng SD, Zhang ZJ, Chen Y. Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers. Arzneimittelforschung. 2008
- Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002
- Shirane M, Nakamura K. Aniracetam enhances cortical dopamine and serotonin release via cholinergic and glutamatergic mechanisms in SHRSP. Brain Res. 2001
- Nakada Y, Yokoyama O, Komatsu K, Kodama K, Yotsuyanagi S, Niikura S, Nagasaka Y, Namiki M. Effects of aniracetam on bladder overactivity in rats with cerebral infarction. J Pharmacol Exp Ther. 2000
- Ouchi Y, Kakiuchi T, Okada H, Nishiyama S, Tsukada H. The effect of aniracetam on cerebral glucose metabolism in rats after lesioning of the basal forebrain measured by PET. J Neurol Sci. 1999
- Pittaluga A, Bonfanti A, Arvigo D, Raiteri M. Aniracetam, 1-BCP and cyclothiazide differentially modulate the function of NMDA and AMPA receptors mediating enhancement of noradrenaline release in rat hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol. 1999
- Kolta A, Lynch G, Ambros-Ingerson J. Effects of aniracetam after LTP induction are suggestive of interactions on the kinetics of the AMPA receptor channel. Brain Res. 1998
- Himori N, Suzuki T, Ueno K. Aniracetam, a pyrrolidinone-type cognition enhancer, attenuates the hydroxyl free radical formation in the brain of mice with brain ischaemia. J Pharm Pharmacol. 1995
- Lee CR, Benfield P. Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. Drugs Aging. 1994
- Kuwahara A, Kubota A, Hakkei M, Nakamura K. [Drug dependence test on a cerebral insufficiency improver, aniracetam]. Nihon Yakurigaku Zasshi. 1987
- Baranova AI, Whiting MD, Hamm RJ. Delayed, post-injury treatment with aniracetam improves cognitive performance after traumatic brain injury in rats. J Neurotrauma. 2006
- Gabryel B, Pudelko A, Malecki A. Erk1/2 and Akt kinases are involved in the protective effect of aniracetam in astrocytes subjected to simulated ischemia in vitro. Eur J Pharmacol. 2004
- Moriya T, Ikeda M, Teshima K, Hara R, Kuriyama K, Yoshioka T, Allen CN, Shibata S. Facilitation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor transmission in the suprachiasmatic nucleus by aniracetam enhances photic responses of the biological clock in rodents. J Neurochem. 2003
- Tanaka Y, Kurasawa M, Nakamura K. Cholinergic and dopaminergic mechanisms involved in the recovery of circadian anticipation by aniracetam in aged rats. Pharmacol Biochem Behav. 2002
- Nakamura K, Tanaka Y. Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology (Berl). 2001
- Nakamura K, Kurasawa M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001
- Galeotti N, Ghelardini C, Bartolini A. Piracetam and aniracetam antagonism of centrally active drug-induced antinociception. Pharmacol Biochem Behav. 1996
- Fallarino F, Genazzani AA, Silla S, L'Episcopo MR, Camici O, Corazzi L, Nicoletti F, Fioretti MC. [3H]aniracetam binds to specific recognition sites in brain membranes. J Neurochem. 1995
- Toide K. Effects of aniracetam on one-trial passive avoidance tests and cholinergic neurons in discrete brain regions of rats. Arch Int Pharmacodyn Ther. 1989
- Yu S, Cai J. Effects of aniracetam on extracellular levels of transmitter amino acids in the hippocampus of the conscious gerbils: an intracranial microdialysis study. Neurosci Lett. 2003
- Tsuzuki K, Takeuchi T, Ozawa S. Agonist- and subunit-dependent potentiation of glutamate receptors by a nootropic drug aniracetam. Brain Res Mol Brain Res. 1992
- Yamada K, Inoue T, Tanaka M, Furukawa T. Prolongation of latencies for passive avoidance responses in rats treated with aniracetam or piracetam. Pharmacol Biochem Behav. 1985
- Gabryel B, Chalimoniuk M, Ma?ecki A, Strosznajder J. Effect of aniracetam on phosphatidylinositol transfer protein alpha in cytosolic and plasma membrane fractions of astrocytes subjected to simulated ischemia in vitro. Pharmacol Rep. 2005
- Nakamura K, Shirane M. Activation of the reticulothalamic cholinergic pathway by the major metabolites of aniracetam. Eur J Pharmacol. 1999
- Staubli U, Ambros-Ingerson J, Lynch G. Receptor changes and LTP: an analysis using aniracetam, a drug that reversibly modifies glutamate (AMPA) receptors. Hippocampus. 1992
- Ventra C, Grimaldi M, Meucci O, Scorziello A, Apicella A, Filetti E, Marino A, Schettini G. Aniracetam improves behavioural responses and facilitates signal transduction in the rat brain. J Psychopharmacol. 1994
- Li Y, Wang JJ, Cai JX. Aniracetam restores the effects of amyloid-beta protein or ageing on membrane fluidity and intracellular calcium concentration in mice synaptosomes. J Neural Transm. 2007
- Wijayawardhane N, Shonesy BC, Vaglenova J, Vaithianathan T, Carpenter M, Breese CR, Dityatev A, Suppiramaniam V. Postnatal aniracetam treatment improves prenatal ethanol induced attenuation of AMPA receptor-mediated synaptic transmission. Neurobiol Dis. 2007
- Gabryel B, Adamczyk J, Huzarska M, Pude?ko A, Trzeciak HI. Aniracetam attenuates apoptosis of astrocytes subjected to simulated ischemia in vitro. Neurotoxicology. 2002
- Nakamura K, Shirane M, Koshikawa N. Site-specific activation of dopamine and serotonin transmission by aniracetam in the mesocorticolimbic pathway of rats. Brain Res. 2001
- Pizzi M, Consolandi O, Memo M, Spano P. N-methyl-D-aspartate neurotoxicity in hippocampal slices: protection by aniracetam. Eur J Pharmacol. 1995
- Himori N, Mishima K. Amelioration by aniracetam of abnormalities as revealed in choice reaction performance and shuttle behavior. Pharmacol Biochem Behav. 1994
- Cumin R, Bandle EF, Gamzu E, Haefely WE. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berl). 1982
- Lawrence JJ, Brenowitz S, Trussell LO. The mechanism of action of aniracetam at synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: indirect and direct effects on desensitization. Mol Pharmacol. 2003
- Togashi H, Nakamura K, Matsumoto M, Ueno K, Ohashi S, Saito H, Yoshioka M. Aniracetam enhances glutamatergic transmission in the prefrontal cortex of stroke-prone spontaneously hypertensive rats. Neurosci Lett. 2002
- Shen Y, Lu T, Yang XL. Modulation of desensitization at glutamate receptors in isolated crucian carp horizontal cells by concanavalin A, cyclothiazide, aniracetam and PEPA. Neuroscience. 1999
- Ito I, Tanabe S, Kohda A, Sugiyama H. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol. 1990
- Pan Y, Dai T, Yang Q. [Influence of aniracetam on the learning ability, memory ability and the expression of BCL-2 of hippocampal in vascular dementia model rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2009
- Zhang J, Liang J, Tian Y, Zhang Z, Chen Y. Sensitive and selective liquid chromatography-tandem mass spectrometry method for the quantification of aniracetam in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007
- Smith AM, Wehner JM. Aniracetam improves contextual fear conditioning and increases hippocampal gamma-PKC activation in DBA/2J mice. Hippocampus. 2002
- Nakamura K, Kurasawa M. Aniracetam restores motivation reduced by satiation in a choice reaction task in aged rats. Pharmacol Biochem Behav. 2001
- Kimura M, Okano S, Inoué S. Effects of aniracetam on impaired sleep patterns in stroke-prone spontaneously hypertensive rats. Psychiatry Clin Neurosci. 2000
- Zajaczkowski W, Danysz W. Effects of D-cycloserine and aniracetam on spatial learning in rats with entorhinal cortex lesions. Pharmacol Biochem Behav. 1997
- Fushiki S, Matsumoto K, Nagata A. Neurite outgrowth of murine cerebellar granule cells can be enhanced by aniracetam with or without alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA). Neurosci Lett. 1995
- Martin JR, Moreau JL, Jenck F. Aniracetam reverses memory impairment in rats. Pharmacol Res. 1995
- Xiao P, Staubli U, Kessler M, Lynch G. Selective effects of aniracetam across receptor types and forms of synaptic facilitation in hippocampus. Hippocampus. 1991
- Kraaier V, van Huffelen AC, Wieneke GH. The hyperventilation-induced ischaemia model in human neuropharmacology: neurophysiological and psychometric studies of aniracetam and 3-OH aniracetam. Eur J Clin Pharmacol. 1989
- Wijayawardhane N, Shonesy BC, Vaithianathan T, Pandiella N, Vaglenova J, Breese CR, Dityatev A, Suppiramaniam V. Ameliorating effects of preadolescent aniracetam treatment on prenatal ethanol-induced impairment in AMPA receptor activity. Neurobiol Dis. 2008
- Rao Y, Xiao P, Xu S. Effects of intrahippocampal aniracetam treatment on Y-maze avoidance learning performance and behavioral long-term potentiation in dentate gyrus in rat. Neurosci Lett. 2001
- Isaacson JS, Nicoll RA. Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus. Proc Natl Acad Sci U S A. 1991
- Ozawa S, Iino M, Abe M. Excitatory synapse in the rat hippocampus in tissue culture and effects of aniracetam. Neurosci Res. 1991
- Spignoli G, Pepeu G. Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol Biochem Behav. 1987
- Petkov VD, Grahovska T, Petkov VV, Konstantinova E, Stancheva S. Changes in the brain biogenic monoamines of rats, induced by piracetam and aniracetam. Acta Physiol Pharmacol Bulg. 1984
- Nakamura K, Kurasawa M. Serotonergic mechanisms involved in the attentional and vigilance task performance of rats and the palliative action of aniracetam. Naunyn Schmiedebergs Arch Pharmacol. 2000
- Boxall AR, Garthwaite J. Synaptic excitation mediated by AMPA receptors in rat cerebellar slices is selectively enhanced by aniracetam and cyclothiazide. Neurochem Res. 1995
- Martin JR, Cumin R, Aschwanden W, Moreau JL, Jenck F, Haefely WE. Aniracetam improves radial maze performance in rats. Neuroreport. 1992
- Canonico V, Forgione L, Paoletti C, Casini A, Colonna CV, Bertini M, Acito R, Rengo F. [Efficacy and tolerance of aniracetam in elderly patients with primary or secondary mental deterioration]. Riv Neurol. 1991
- Stancheva SL, Alova LG. [Effect of centrophenoxine, piracetam and aniracetam on the monoamine oxidase activity in different brain structures of rats]. Farmakol Toksikol. 1988
- Sourander LB, Portin R, Mölsä P, Lahdes A, Rinne UK. Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent. Psychopharmacology (Berl). 1987
- Saletu B, Grünberger J. The hypoxia model in human psychopharmacology: neurophysiological and psychometric studies with aniracetam i.v. Hum Neurobiol. 1984
- Vaglenova J, Pandiella N, Wijayawardhane N, Vaithianathan T, Birru S, Breese C, Suppiramaniam V, Randal C. Aniracetam reversed learning and memory deficits following prenatal ethanol exposure by modulating functions of synaptic AMPA receptors. Neuropsychopharmacology. 2008
- Tanaka Y, Kurasawa M, Nakamura K. Recovery of diminished mealtime-associated anticipatory behavior by aniracetam in aged rats. Pharmacol Biochem Behav. 2000
- Ghamari-Langroudi M, Glavinovíc MI. Changes of spontaneous miniature excitatory postsynaptic currents in rat hippocampal pyramidal cells induced by aniracetam. Pflugers Arch. 1998
- Partin KM, Fleck MW, Mayer ML. AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate. J Neurosci. 1996
- Johansen TH, Chaudhary A, Verdoorn TA. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors. Mol Pharmacol. 1995
- Pizzi M, Fallacara C, Arrighi V, Memo M, Spano PF. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J Neurochem. 1993
- Koike H, Saito H, Matsuki N. Inhibitory effect of aniracetam on N-type calcium current in acutely isolated rat neuronal cells. Jpn J Pharmacol. 1993
- Chapman AG, al-Zubaidy Z, Meldrum BS. Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 mice. Eur J Pharmacol. 1993
- Somnier FE, Ostergaard MS, Boysen G, Bruhn P, Mikkelsen BO. Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents. A randomized, double-blind, placebo-controlled cross-over study with neuropsychological tests. Psychopharmacology (Berl). 1990
- Senin U, Abate G, Fieschi C, Gori G, Guala A, Marini G, Villardita C, Parnetti L. Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study. Eur Neuropsychopharmacol. 1991
- Pontecorvo MJ, Evans HL. Effects of aniracetam on delayed matching-to-sample performance of monkeys and pigeons. Pharmacol Biochem Behav. 1985
- Nakamura K, Kurasawa M, Tanaka Y. Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam. Eur J Pharmacol. 1998
- Endo H, Tajima T, Yamada H, Igata A, Yamamoto Y, Tsuchida H, Nakashima Y, Suzuki Y, Ikari H, Iguchi A. Pharmacokinetic study of aniracetam in elderly patients with cerebrovascular disease. Behav Brain Res. 1997
- Petkov VD, Mosharrof AH, Milenkov B, Enev V. Learning and memory effects of four newly-synthesized aniracetam analogues. Acta Physiol Pharmacol Bulg. 1989
- Satoh M, Ishihara K, Iwama T, Takagi H. Aniracetam augments, and midazolam inhibits, the long-term potentiation in guinea-pig hippocampal slices. Neurosci Lett. 1986
- Foltyn P, Lücker PW, Schnitker J, Wetzelsberger N. [A test model for cerebrally-active drugs as demonstrated by the example of the new substance aniracetam]. Arzneimittelforschung. 1983
- Nishizaki T, Matsumura T. The aniracetam metabolite 2-pyrrolidinone induces a long-term enhancement in AMPA receptor responses via a CaMKII pathway. Brain Res Mol Brain Res. 2002
- Nakamura K, Kurasawa M, Shirane M. Impulsivity and AMPA receptors: aniracetam ameliorates impulsive behavior induced by a blockade of AMPA receptors in rats. Brain Res. 2000
- Ogiso T, Uchiyama K, Suzuki H, Yoshimoro M, Tanino T, Iwakai M, Uno S. Pharmacokinetics of aniracetam and its metabolites in rat brain. Biol Pharm Bull. 2000
- Katsunuma H, Shimizu T, Ogawa K, Kubo H, Ishida H, Yoshihama A. Treatment of insomnia by concomitant therapy with Zopiclone and Aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci. 1998
- Ogiso T, Iwaki M, Tanino T, Ikeda K, Paku T, Horibe Y, Suzuki H. Pharmacokinetics of aniracetam and its metabolites in rats. J Pharm Sci. 1998
- Tang CM, Shi QY, Katchman A, Lynch G. Modulation of the time course of fast EPSCs and glutamate channel kinetics by aniracetam. Science. 1991
- Guenzi A, Zanetti M. Determination of aniracetam and its main metabolite, N-anisoyl-GABA, in human plasma by high-performance liquid chromatography. J Chromatogr. 1990
- Bartolini L, Casamenti F, Pepeu G. Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions. Pharmacol Biochem Behav. 1996
- Wang YF, Li CC, Cai JX. Aniracetam attenuates H2O2-induced deficiency of neuron viability, mitochondria potential and hippocampal long-term potentiation of mice in vitro. Neurosci Bull. 2006
- Wesnes K, Anand R, Simpson P, Christmas L. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. J Psychopharmacol. 1990
- Cai S, Wang L. Determination of aniracetam's main metabolite, N-anisoyl-GABA, in human plasma by LC-MS/MS and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2012
- Asztely F, Hanse E, Wigström H, Gustafsson B. Aniracetam-evoked potentiation does not interact with long-term potentiation in the CA1 region of the hippocampus. Synapse. 1992
- Pontecorvo MJ, Evans HL. Effects of aniracetam upon the delayed matching-to-sample performance of monkeys and pigeons. Ann N Y Acad Sci. 1985
- Schwam E, Keim K, Cumin R, Gamzu E, Sepinwall J. The effects of aniracetam on primate behavior and EEG. Ann N Y Acad Sci. 1985
- Mizuki Y, Yamada M, Kato I, Takada Y, Tsujimaru S, Inanaga K, Tanaka M. Effects of aniracetam, a nootropic drug, in senile dementia--a preliminary report. Kurume Med J. 1984
- Nagasaka T, Togashi S, Amino A, Nitta K, Shindo K, Shiozawa Z. Aniracetam for treatment of patients with progressive supranuclear palsy. Eur Neurol. 1997
- Vincent G, Verderese A, Gamzu E. The effects of aniracetam (Ro 13-5057) on the enhancement and protection of memory. Ann N Y Acad Sci. 1985
- Mayersohn, M., Roncari, G. & Wendt, G. Drug Invest (1993) 5(Suppl 1): 73. https://doi.org/10.1007/BF03258429
Article last updated on: May 24th, 2018 by Nootriment
19 Comments
Couldn’t get past the fact you didn’t mention anything about glutamate or ampakine receptors in the section regarding how Aniracetam works. Or the fact that its lipid soluble and you didn’t mention the relevance as far as availability is concerned. You are aware you cited 96 articles and this entire article at its best reads like a poorly understood regurgitated Wikipedia article. Not trying to give you a hard time, but i’m sure there’s other people like me that have been on this site looking for more, scientific unbiased-reading factual information and have been let down by a lot of fluff and emotion and …you get the idea. Also, acetylcholine is NOT the primary reason for Aniracetams effects, fyi. Allosteric modulation of the actual receptors for glutamate receptors, specifically ampakine sub-types has a lot to do with the effects as well. No mention of long term potentiation or general information on ampakines in general, how they work, there effects ect. severely limit your readers ability to accurately understand how aniracetam works, and makes people who understand how aniracetam works question all of your claims. Just saying, have a great day though! I tried to be constructive.
Hi Matt,
Thanks for your feedback. We have 27 articles on Aniracetam on the site and you’ll find the information you’re looking for regarding AMPA receptors at https://nootriment.com/aniracetam-effects/ as well as its fat-solubility in this article https://nootriment.com/pramiracetam-aniracetam-fat-soluble/
We’ve tried as much as possible to balance providing the scientific research you’re looking for while still making the site accessible and easy to understand for new users who might not have as much of a rigorous neuroscience background :).
Hey Matt,
Can you provide any links of articles that are more informative re Aniracetam… or, as you said: “scientific unbiased-reading factual information”.
I am completely new to nootropics and would really like to get as much info as I can before making a choice as to which one(s) to try.
Thanks in advance!
Liz
bioavailability **
This is not a scientific email. The only nootropics that I am familiar with and take regularly (in cycles) are Sulbutiamine and Choline. I absolutely love them. My memory and recall have definately improved and I really can’t say enough about the benefits of taking these supplements. This is why I chose to add Aniracetam. Well, for me, it was a big mistake. Very soon after I took it (exactly as directed-no more, no less and with fish oil supplement) I felt sluggish, groggy, and began to see colors and everything seemed to be in very slow motion. I literally got scared. It was almost like being on a very strange acid trip. You kind of seemed to be on the outside of yourself looking in. I had to sit down for awhile, hold my head, and kind of let things “flow”. I called my boyfriend who came and sat with me until these “strange” feelings subsided which I do have to say took awhile. During this time, inanimate objects to move and float.
Bottom line to my review…I have NO idea what happened between myself and Aniracetam. I had read that it had an anxiolytic effect. Well, I didn’t so much feel ANXIOUS..just scared. The scared feeling did pass rather quickly and things just “happened” and I had to let everything pass and then things around me returned to normal, my mood was stable but no better than before taking this. My memory was perhaps a bit enhanced. I did remember very clearly what had just happened and the colors that flashed before me were extrememly bright and vivid. The images I saw were very clear. My recall of it all was very much on point. My energy though, was way down.
So, needless to say, I have an entire bottle of Aniracetam (minus 1) sitting in a drawer at home. I’m saving it (I guess) for anyone that wants to experience a very very unusual trip that ends with an amazing recall.
Hi Courtney,
Thanks for sharing your experience. Did you ever use Aniracetam again? It would be very interesting to know what sort of effects occurred and whether the initial effects were repeated upon second use.
Hi my name is Bo and I am a student majoring in science at Portland State University and the proprietor of a review channel on youtube. Currently I have started a series on nootropic reviews and I am interested in reviewing several of your nootropics, particularly the racetams, and perhaps others including noopept, phenibut and other products you would like to have reviewed. If you are interested in providing some of these products that I may give my honest review on (I certainly understand many nootropics and supplements result in subjective results and take this into consideration) please let me know and I would be happy to mention your company name as it was given to me by a reliable source to be among the highest in terms of providing purity in your products. Thank you for your time.
Hi Bo,
Thanks for your comment and good luck on your YouTube show! We don’t produce any of our own products, nor do we sell products directly. All of the products you see on the site are ads for other companies. You may want to get in touch with them if you would like to get samples to review.
Thanks
Q) Has anyone got some experiences which they would be able to share, including advice on the starting dose(s), how often to take per day, and what happens during a ‘wash out period’ (of, say, a few weeks) in regards to both panic disorder (and PTSD, including social anxiety disorder) if one has been taking Aniracetam (and/or Phenibut) on a daily/regular basis?
Q) Also, how does one withdraw from xanax (alprazolam) whilst beginning and taking the two aforementioned nootropics?
On 2 occasions some years ago I suddenly stopped xanax and ended up having seizures: the first time I was not aware of the risks and the second time was after a serious injury, the pain (and being pumped full of strong analgesia) meant I wasn’t aware enough to let the ICU doctors know about the need for maintaining the daily doses of xanax.
Recently my new GP, not fond of benzodiazepenes even when no other medications or treatment modalities have failed to reduce panic attacks, decided to require that I start to withdraw from xanax and he created a regime which dropped my dose down much too quickly and I wasn’t able to cope with the side-effects. So whilst he is wanting to try again, being determined to see me xanax-free after many years of regular daily doses (which have not increased but remained steady now for at least 4-5 years), I’m wondering about Aniracetam (and Phenibut) to be used both whilst withdrawing from xanax and as a replacement for xanax – which is mentioned by a few individuals in the comments above.
I would be very grateful for information about this matter.
Q) Specifically, I am wondering about the use of Aniracetam (and/or Phenibut) to address panic disorder (as well as PTSD: C-PTSD to be exact) and particularly in regards to whether these two nootropics are a replacement for xanax, keeping in mind that both nootropics AND xanax create physical dependence (and perhaps psychological addiction?) and have serious side-effects when suddenly stopping or even, apparently, when trying to slowly withdraw from the drugs.
Q) What doses of Aniracetam and/or Phenibut have people taken and/or are continuing to take to deal with anxiety, panic disorder, and/or PTSD?
Q) How does one deal with taking a few days to a few weeks off the nootropics considering the withdrawal symptoms that occur when suddenly stopped?
Q) Does – or has – anyone take(n) either (or both) of the nootropics without a break, and how has the experience of withdrawal compared to that of withdrawing from xanax?
I have read that some people believe Aniracetam is safer than benzodiazepenes in regards to anxiety disorders. This does make me wonder whether Aniracetam and/or Phenibut are a safer alternative to xanax, whether they can be used when withdrawing from xanax after many years of daily xanax intake (under a doctor’s supervision), and what people’s experiences with suddenly stopping and also dropping the dose (to withdraw from the nootropics) have been like?
I have taken Aniracetam (and Phenibut) on two (2) separate occasions and was pleasantly surprised by the effects both as an anxiolytic and in not only acting like an anti-depressant (without the jittery, headachey etc side effects!) but in improving my mood quite noticeably. But I am a bit hesitant to take either of these 2 nootropics on anything like a regular basis without the answers to my concerns as stated here.
Please let me know if you can answer some of my questions here since looking at the side-effects and information about the nootropics both here and on other sites doesn’t answer these questions, and I would like to be able to address the panic disorder (plus social anxiety and PTSD) without reliance on xanax but am concerned about the risks of Aniracetam (as well as Phenibut) – and my quite conservative doctor does not know anything about nootropics and definitely would not support their use for any purpose.
If there is a good, reputable forum which is fairly active and where my concerns regarding Aniracetam (and Phenibut, also, if possible) have been or can be addressed by other individuals I would be very grateful to know where to find it!
Hi Laura, thanks for the detailed post with honest questions. I have suffered from mild anxiety and PTSD-like symptoms for several years now and I am currently taking Hydrocodone 3mg/7.5mg for mental pressure relief, along with Pramiracetam, SAM-e 200mg and a custom blend from my primary doctor called Neuro-T Supply (L-Tyrosine, L-Lysine, Inositol, 5HTP, P5P, L-Tryptophan, Thiamin pyrophosphate). I am going to order some Aniracetam to see if it helps with focus, mental fluidity and learning capacity as this editorial post mentions. I am currently studying for some exams and can post my results here after giving it some evaluation time.
Hi.. I’m trying to figure out which would be the best stack for me… Would Aniracetam Piracetam be more effective for my first nootropic stack or is Aniracetam Oxiracetam better?
Also… is there any reason why you don’t mention the Aniracetam Pramiracetam stack? Is it because they are more similar in their mechanism of action? Would there be too much overlap to make it worth it?
Hey Marco,
Most nootropic users start out with Piracetam and Aniracetam for their first Racetam stack. All of this is up for debate and subject to personal experiences and opinions.
Given than Piracetam has such a low cost per dosage, it is sometimes preferred as a first nootropic. Some people find that an Aniracetam Oxiracetam stack is too stimulating, while others prefer the heightened focus and attention associated with this combination.
It’s also possible to stack Aniracetam and Pramiracetam. I’ve used this stack before and find it provides a good balance of goal-oriented behaviour without feeling thoughts go into overdrive.
Another option for a stack is Noopept, which is a solid all-around nootropic and has the best cost efficacy of all of the Racetams.
Could I stack this with GABA supplements if I really want it mostly for the anxiolytic effects? Would there be any benefits to this?
Hey Gerry,
Thanks for submitting your question! There is a lot of debate about whether GABA supplements are effective due to the low penetration of the blood-brain barrier that they exhibit. PharmaGABA is a form of gamma-aminobutyric acid that is purported to be better at transporting across the BBB and may stimulate GABA receptors outside of the Central Nervous System.
If your main goal is to increase the anxiolytic effects of Aniracetam, this supplement may be beneficial for you, but there are no studies that have specifically looked at whether there is a complementary effect between these two compounds.
For anxiety, it is more common to stack Aniracetam with Phenibut or Picamilon. Other natural supplement alternatives include L-Theanine, Inositol, Kava, Valerian Root, 5-HTP, L-Tryptophan and Lemon Balm. One often overlooked supplement for anxiety is a low dose of melatonin. There is growing research suggesting that daytime use of this supplement can have a calming effect and attentuate feelings of anxiety.
What would be the best dosage of Aniracetam if my main goal is to get rid of my brain fog so I can be more focused at school? I want something to help me become less distracted.
Hi Arthur,
Thanks for your question. It is generally recommended to start with the lowest therapeutic dosage and to gradually increase from there as necessary. In research studies, dosages of 600 mg per day (split into 3 x 200 mg per day) have been effective for certain outcomes. As a nootropic, many users start with a dosage of 750 mg per day to gauge their individual tolerance level and adjust from there.
One thing I notice when I use Aniracetam is almost a euphoric reaction to music… it makes sounds have so much more detail and nuance.
Just want to say your article is as astounding. The clarity in your post
is simply cool and i can assume you are an expert on this subject.
Well with your permission let me to grab your feed to keep updated with forthcoming post.
Thanks a million and please keep up the gratifying work.
Wow, awesome and vast article, I think I have to read it twice or three times to fully get all of the info here haha. Thanks!